BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22289436)

  • 1. Liposomes for intravitreal drug delivery: a state of the art.
    Bochot A; Fattal E
    J Control Release; 2012 Jul; 161(2):628-34. PubMed ID: 22289436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Potential of liposomes for the intravitreal injection of therapeutic molecules].
    Bochot A; Lajavardi L; Camelo S; Bourges JL; Behar-Cohen F; de Kozak Y; Fattal E
    Ann Pharm Fr; 2011 Mar; 69(2):100-7. PubMed ID: 21440102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug delivery to the posterior segment of the eye.
    Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
    Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination and pharmacokinetic profile of liposomal foscarnet in rabbit ocular tissues after intravitreal administration.
    Claro C; Ruiz R; Cordero E; Pastor MT; López-Cortés LF; Jiménez-Castellanos M; Lucero M
    Exp Eye Res; 2009 Mar; 88(3):528-34. PubMed ID: 19084004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel drug delivery systems for retinal diseases. A review.
    Lee SS; Robinson MR
    Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotherapy for posterior eye diseases.
    Kaur IP; Kakkar S
    J Control Release; 2014 Nov; 193():100-12. PubMed ID: 24862316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of liposomes as intravitreal drug delivery system].
    Bejjani RA; Jeanny JC; Bochot A; Behar-Cohen F
    J Fr Ophtalmol; 2003 Nov; 26(9):981-5. PubMed ID: 14631286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug.
    Cheng L; Hostetler KY; Gardner MF; Avila CP; Bergeron-Lynn G; Keefe KS; Wiley CA; Freeman WR
    Invest Ophthalmol Vis Sci; 1999 Jun; 40(7):1487-95. PubMed ID: 10359331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes.
    Bochot A; Fattal E; Boutet V; Deverre JR; Jeanny JC; Chacun H; Couvreur P
    Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):253-9. PubMed ID: 11773039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drainage of fluorescent liposomes from the vitreous to cervical lymph nodes via conjunctival lymphatics.
    Camelo S; Lajavardi L; Bochot A; Goldenberg B; Naud MC; Fattal E; Behar-Cohen F; de Kozak Y
    Ophthalmic Res; 2008; 40(3-4):145-50. PubMed ID: 18421229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical devices for the treatment of eye diseases.
    Yasukawa T; Ogura Y
    Handb Exp Pharmacol; 2010; (197):469-89. PubMed ID: 20217540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.
    Behar-Cohen FF; El Aouni A; Gautier S; David G; Davis J; Chapon P; Parel JM
    Exp Eye Res; 2002 Jan; 74(1):51-9. PubMed ID: 11878818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes.
    Zhang R; He R; Qian J; Guo J; Xue K; Yuan YF
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3575-82. PubMed ID: 20164461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal triamcinolone acetonide: a change in a paradigm.
    Jonas JB
    Ophthalmic Res; 2006; 38(4):218-45. PubMed ID: 16763379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periocular routes for retinal drug delivery.
    Raghava S; Hammond M; Kompella UB
    Expert Opin Drug Deliv; 2004 Nov; 1(1):99-114. PubMed ID: 16296723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.
    Lajavardi L; Bochot A; Camelo S; Goldenberg B; Naud MC; Behar-Cohen F; Fattal E; de Kozak Y
    Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3230-8. PubMed ID: 17591893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation.
    Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Keefe KS; Bergeron-Lynn G; Severson GM; Soules KA; Mueller AJ; Freeman WR
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1523-32. PubMed ID: 10798672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gel and solid matrix systems for the controlled delivery of drug carrier-associated nucleic acids.
    Fattal E; De Rosa G; Bochot A
    Int J Pharm; 2004 Jun; 277(1-2):25-30. PubMed ID: 15158966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.